Mon. 6 May 2024, 6:04am ET
Benzinga
News
ADC Therapeutics SA (NYSE:ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).